NCT03395197 2026-03-12
TALAPRO-2
Pfizer
Phase 3 Active not recruiting
Clinical Trials
5 trialsNCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT03901469 2025-10-07
TNBC
Zenith Epigenetics
Phase 2 Terminated
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated